Regeneron Pharmaceuticals Inc

RBC has increased its price target for Regeneron stock from USD 737.00 to USD 810.00, maintaining a Sector Perform rating. This adjustment follows Regeneron's reported second-quarter revenue of USD 4.29 billion, a 16.70 percent increase year-over-year. Investors are now looking towards the company's third-quarter results, scheduled for October 30, 2026, to assess continued growth.

Cantor Fitzgerald has reiterated an Overweight rating on CytomX Therapeutics (NASDAQ: CTMX) with a $12 price target, citing the company's approach to a pivotal inflection point. Despite a 40% year-to-date stock decline, the firm believes the current valuation is modest for a program nearing Phase 3 in 2027. Recent news also noted CytomX's wider-than-expected Q2 2026 loss, but highlighted substantial cash reserves and promising early data for its lead cancer drug.

Regeneron Pharmaceuticals reported positive 84-week Pasatru results, showing zero new heterotopic ossification lesions compared to nine for placebo in the OPTIMA extension trial. Citi maintained a Hold rating and a $740 price target for Regeneron stock, which was trading at EUR 687.20 on October 13, 2026. Investors are anticipating the third-quarter 2026 results on October 30, 2026, to assess if revenue growth translates into earnings growth.

Regeneron Pharmaceuticals reported positive 84-week Phase 3 results for Pasatru in adults with fibrodysplasia ossificans progressiva, noting no new heterotopic ossification lesions were observed from week 56 to week 84 for Pasatru recipients. The stock was trading pre-market at EUR 684.95 at Lang & Schwarz on October 13, 2026. These findings were presented at the American Society for Bone and Mineral Research annual meeting.

Regeneron Pharmaceuticals reported positive long-term results for its rare disease drug, Pasatru, which treats fibrodysplasia ossificans progressiva (FOP). An extended Phase 3 trial showed zero new abnormal bone growth in patients taking Pasatru, leading to a 2.8% rise in REGN shares. The company plans a new study for children and continues to expand its drug pipeline beyond Pasatru, including treatments for cancer and eye diseases.

Regeneron Pharmaceuticals announced positive 84-week results from its Phase 3 OPTIMA trial for Pasatru (garetosmab-grts), a drug treating fibrodysplasia ossificans progressiva (FOP). The drug effectively halted new abnormal bone growth and significantly reduced disease flare-ups, with a sustained safety profile. Regeneron plans to initiate another Phase 3 trial for adolescents and children with FOP.

Regeneron announced that its drug Pasatru demonstrated sustained benefit in the OPTIMA trial extension for a genetic disorder. This news follows several recent analyst target price adjustments for Regeneron Pharmaceuticals, Inc., with RBC, Morgan Stanley, JPMorgan, and Jefferies all raising their price targets in early October. The company also recently presented new clinical research at the European Society for Medical Oncology Congress 2026 and announced positive results from trials for Trevogrumab and Ubamatamab.

Shares of Regeneron Pharmaceuticals Inc. (REGN) rose 2.18% to $762.81 on Monday, marking its second consecutive day of gains. This performance outpaced the broader market, as the Dow Jones Industrial Average (DJIA) gained 0.38% while the S&P 500 Index (SPX) fell 0.06%.

Regeneron Pharmaceuticals announced positive 84-week results from the Phase 3 OPTIMA trial for Pasatru (garetosmab-grts), an FDA-approved treatment for fibrodysplasia ossificans progressiva (FOP). The trial demonstrated sustained efficacy in preventing new heterotopic ossification (HO) lesions and significantly reducing disease flare-ups, with a consistent and generally well-tolerated safety profile. Pasatru is the first and only FDA-approved treatment for FOP, and further studies, including a trial for adolescents and children, are planned.

Bristol Myers Squibb's experimental lung drug, admilparant, showed mixed results in a Phase 3 trial for idiopathic pulmonary fibrosis. While the lower 60mg dose significantly slowed breathing capacity decline, the higher 120mg dose did not meet statistical significance, leading to "confounding" questions from analysts. Despite the mixed data and prior safety concerns, the drug's success at the lower dose is still seen by some as a potential blockbuster opportunity, though shares initially dipped.